Abingdon Health (LSE:ABDX) EBIT : £-2.30 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Abingdon Health EBIT?

Abingdon Health's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was £-1.19 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was £-2.30 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Abingdon Health's annualized ROC % for the quarter that ended in Dec. 2023 was -175.91%. Abingdon Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -217.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Abingdon Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -17.72%.

Abingdon Health EBIT Historical Data

The historical data trend for Abingdon Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abingdon Health EBIT Chart

Abingdon Health Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT

Get a 7-Day Free Trial

-1.39

-3.31

-6.72

-21.52

-3.48

Abingdon Health Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial					-5.69	-15.83	-2.38	-1.11	-1.19

Competitive Comparison of Abingdon Health's EBIT

For the Diagnostics & Research subindustry, Abingdon Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abingdon Health's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Abingdon Health's EV-to-EBIT falls into.

Abingdon Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-2.30 Mil.

Abingdon Health (LSE:ABDX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Abingdon Health's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-2.928 * ( 1 - 1.23% )	/	( (2.123	+	1.165)	/ 2 )
=	-2.8919856	/	1.644
=	-175.91 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.061	-	1.296	-	( 3.236	-	max(0, 2.12	-	4.762	+	3.236	))
=	2.123

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.822	-	2	-	( 1.998	-	max(0, 2.097	-	3.754	+	1.998	))
=	1.165

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Abingdon Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.372	/	( ( (1.209 + max(-1.114, 0))	+	(0.977 + max(-0.244, 0)) )	/	2 )
=	-2.372	/	( ( 1.209	+	0.977 )	/	2 )
=	-2.372	/	1.093
=	-217.02 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.491	+	0.329	+	0.098999999999999)	-	(1.296	+	0	+	0.737)
=	-1.114

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.999	+	0.411	+	0.346)	-	(2	+	0	+	0)
=	-0.244

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Abingdon Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-2.295	/	12.949
	=	-17.72 %

Abingdon Health EBIT Related Terms

Thank you for viewing the detailed overview of Abingdon Health's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Abingdon Health (LSE:ABDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abingdon Health PLC (LSE:ABDX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

York Biotech Campus, Sand Hutton, York, GBR, YO41 1LZ

Website

https://www.abingdonhealth.com

Abingdon Health PLC is a technology-enabled lateral flow diagnostics company. It provides rapid testing solutions to clients in healthcare and other industries. The firm's product ABC-19 is an antibody test for Covid-19 , and also produces tests covering areas such as self-test HIV, equine infection, human fertility, etc. Business operating segments includes; Contract Development comprises development work for third parties. Contract Manufacturing comprises contract development and manufacturing activities. Product Sales comprises the sale of ABC-19, Pocket Diagnostic products, PCRD tests and antibodies for research use. Key revenue comes from Contract Development segment. Geographically it operates and earns revenue from the UK, USA and Canada, Europe and the rest of the world.

Abingdon Health (LSE:ABDX) Headlines

No Headlines